|
1) Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-97
|
|
|
|
2) Zhang JG, Wang JJ, Zhao F, et al. MicroRNA-21 represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta. 2010; 411: 846-52
|
|
|
|
|
|
3) Motoyama K, Inoue H, Mimori K, et al. Clini-copathological and prognostic significance of PDCD4 and microRNA-21 in human gastric can-cer. Int J Oncol. 2010; 36: 1089-95
|
|
|
|
|
|
4) van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A. 2006; 103: 18255-60
|
|
|
|
|
|
5) Ikeda S, Kong SW, Lu J, et al. Altered microRNA expression in human heart disease. Physiol Genom. 2007; 31: 367-73
|
|
|
|
|
|
6) Naga Prasad SV, Duan ZH, Gupta MK, et al. Unique microRNA profile in end-stage heart failure indicates alterations in specific cardio-vascular signaling networks. J Biol Chem. 2009; 284: 27487-99
|
|
|
|
|
|
7) Matkovich SJ, Van Booven DJ, Youker KA, et al. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation. 2009; 119: 1263-71
|
|
|
|
|
|
8) Gupta SK, Bang C, Thum T. Circulating microRNAs as biomarkers and potential para-crine mediators of cardiovascular disease. Circ Cardiovasc Genet. 2010; 3: 484-8
|
|
|
|
|
|
9) Dimmeler S, Zeiher AM. Circulating microRNAs: novel biomarkers for cardiovascular diseases？ Eur Heart J. 2010; 31: 2705-7
|
|
|
|
|
|
10) Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008; 141: 672-5
|
|
|
|
|
|
11) Ai J, Zhang R, Li Y, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun. 2010; 391: 73-7
|
|
|
|
|
|
12) Kuwabara Y, Ono K, Horie T, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate the existence of myocardial damage. Circ Cardiovasc Genet. 2011; 4: 446-54
|
|
|
|
|
|
13) Corsten MF, Dennert R, Jochems S, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet. 2010; 3: 499-506
|
|
|
|
|
|
14) Wang GK, Zhu JQ, Zhang JT, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010; 31: 659-66
|
|
|
|
|
|
15) Tijsen AJ, Creemers EE, Moerland PD, et al. MIRNA423-5p as a circulating biomarker for heart failure. Cir Res. 2010; 106: 1035-9
|
|
|
|
|
|
16) Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 6: 654-9
|
|
|
|
|
|
17) Kosaka N, Iguchi H, Yoshioka Y, et al. Secretory mechanisms and intercellular transfer of micro-RNAs in living cells. J Biol Chem. 2010; 285: 17442-52
|
|
|
|
|
|
18) Zhang Y, Liu D, Chen X, et al. Secreted monocytic miRNA-150 enhances targeted endo-thelial cell migration. Mol Cell. 2010; 39: 133-44
|
|
|
|
|
|
19) Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal. 2009; 2: ra81
|
|
|
|
|
|
20) Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011; 108: 5003-8
|
|
|
|
|